Trial
NCT04474314
A Study of IMR-687 in Subjects With Sickle Cell Disease
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
Cardurion Pharmaceuticals, Inc.
Collaborators
Imara, Inc.
Condition
Sickle Cell Disease
Intervention
IMR-687
Why stopped
A recently conducted Interim analysis of IMR-SCD-301 demonstrated that while IMR-687 was generally well-tolerated, it failed to meet its primary efficacy endpoint. So, the sponsor has decided to discontinue this study.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-05-15